BackAbbvie Overview
Abbvie Inc

Abbvie Target Price

Analysts' average 12-month price target for Abbvie is $280.

Get informed when a big investor buys or sells

+ Follow

Share Price

$249.94

Average Target Price

$279.8412% upside

19 analysts in the last 4 months

High: $300 | Low: $235

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Guggenheim$28815.2% upsideOpen
2026-08-03Morgan Stanley$29618.4% upsideOpen
2026-08-03Canaccord GenuityGary Nachman$29016% upsideOpen
2026-07-29Barclays$30020% upsideOpen
2026-07-22Canaccord Genuity$28212.8% upsideOpen
2026-07-13UBS$2604% upsideOpen
2026-07-13BMO Capital$30020% upsideOpen
2026-07-10RBC CapitalTrung Huynh$28012% upsideOpen
2026-07-10Wells Fargo$29518% upsideOpen
2026-07-09Guggenheim$2614.4% upsideOpen
2026-07-06HSBC$30020% upsideOpen
2026-07-06Cantor Fitzgerald$2656% upsideOpen
2026-06-23Canaccord Genuity$2739.2% upsideOpen
2026-06-22Wells Fargo$2604% upsideOpen
2026-05-15Evercore ISI$2356% downsideOpen
2026-05-14Piper Sandler$29819.2% upsideOpen
2026-04-30Morgan Stanley$27811.2% upsideOpen
2026-04-23Piper Sandler$29417.6% upsideOpen
2026-04-20Canaccord Genuity$2624.8% upsideOpen
2026-04-10GuggenheimVamil Divan$2490.4% downsideOpen
2026-04-08Cantor Fitzgerald$2404% downsideOpen
2026-02-24RBC CapitalTrung Huynh$2604% upsideOpen
2026-02-19Barclays$27510% upsideOpen
2026-02-18Piper Sandler$29919.6% upsideOpen
2026-02-05UBS$2308% downsideOpen
2026-02-04Evercore ISIGavin Clark-Gartner$2288.8% downsideOpen
2026-01-28Goldman SachsAsad Haider$22310.8% downsideOpen
2026-01-20Berenberg Bank$27510% upsideOpen
2026-01-15BMO CapitalEvan David Seigerman$2583.2% upsideOpen
2026-01-07UBS$2404% downsideOpen
2025-12-12Morgan Stanley$2697.6% upsideOpen
2025-12-10HSBC$2656% upsideOpen
2025-11-05Piper SandlerDavid Amsellem$28915.6% upsideOpen
2025-11-03Raymond JamesGary Nachman$2562.4% upsideOpen
2025-10-20Guggenheim$2423.2% downsideOpen
2025-10-17Raymond JamesGary Nachman$2500% upsideOpen
2025-10-10Piper Sandler$28413.6% upsideOpen
2025-10-09Cantor Fitzgerald$2500% upsideOpen
2025-10-03UBS$2510.4% upsideOpen
2025-10-02HSBC$22510% downsideOpen
2025-09-15Cantor FitzgeraldCarter Gould$2452% downsideOpen
2025-02-03Raymond JamesGary Nachman$22012% downsideOpen
2025-02-03BMO CapitalEvan Seigerman$21514% downsideOpen
2024-11-12BMO CapitalEvan David Seigerman$20816.8% downsideOpen
2024-10-31BMO CapitalEvan David Seigerman$2288.8% downsideOpen
2024-10-31Bank of America SecuritiesCharlie Yang$21016% downsideOpen
2024-10-31CitigroupGeoff Meacham$2269.6% downsideOpen
2024-10-18Bank of America SecuritiesGeoff Meacham$19522% downsideOpen
2024-10-17BernsteinCourtney Breen$20318.8% downsideOpen
2024-08-23Raymond JamesChristopher Raymond$20916.4% downsideOpen

Abbvie (ABBV) FAQ

Abbvie posts a target price of $280. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $280 for ABBV means covering analysts, on average, see the stock 12.0% upside of $249.94 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ABBV's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Abbvie's other metric pages and overview cover the third.

Judging Abbvie against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $280 here, then scan peer and history charts to see if the gap is persistent.